Actavis Says Namenda Product-Hopping Suit Has No Hop
Pharmaceutical companies Actavis and Merz told a New York federal court Tuesday they cannot be sued for "product hopping" the Alzheimer's treatment Namenda, because the drug's original version was never pulled...To view the full article, register now.
Already a subscriber? Click here to view full article